尼莫地平治疗无症状脑梗塞认知功能障碍的对照研究

目的探讨尼莫地平对无症状脑梗塞认知功能障碍的改善作用及安全性。方法将80例无症状脑梗塞患者随机分为治疗组和对照组，每组40例，于治疗前及治疗后3月分别进行蒙特利尔认知量表（MoCA）、简易智能状态量表（MMSE）、画钟测验（CDT）评估，并比较2组的评分结果。结果尼莫地平治疗后3月MMSE 评分为（26.35±3.26）分，MoCA评分为（25.53±4.31）分，CDT评分为（6.12±2.23）分，较对照组分别为MMSE 评分为（23.12±3.45）分，MoCA评分为（22.21±3.63）分，CDT评分为（4.35±2.61）分有改善，差异均有统计学意义（P＜0.05）。80例患者中MoCA评测异常组在视空间与执行能力、延迟记忆、注意力及计算力、抽象思维等分项得分明显低于MoCA评测正常组（P＜0.05）。结论尼莫地平能有效改善无症状脑梗塞患者的认知功能，且安全性较高。

Case control study on the effect of Nimodipine in treating cognitive impairment with silent cerebral infarction

Objective To explore the role of nimodipine in improving cognitive function in silent cerebral infarction pa-tients and its safety. Methods Eighty SCI patients were divided randomly into 2 groups.MMSE、MoCA and CDT scores were assessed before treatement and after 3 month of treatment.The results were compared between the 2 groups. Results MMSE、MoCA and CDT scores of Nimodipine group (26.35 ±3.26,25.53 ±4.31,6.12 ±2.23,respectively),improved when com-pared with the control (23.12 ±3.45,22.21 ±3.63,4.35 ±2.61,respectively),and the difference was statistical signifi-cance (P<0.05 ). The patients with abnormal MoCA had lower scores in several cognitive domains (visuospatial and executive abilities,delayed memory,attention and capacity of calculation,abstract thinking (P<0.05 )compared with control group.Conclusion Nimodipine could improve effectively the cognitive function in SCI patients and with a higher safety.